7426 - 7450 of 7877 Results
Title
Year
-
OPENTitle: CNTRICS Imaging Biomarkers Final Task Selection: Long-Term Memory and Reinforcement LearningJournal Name: Schizophrenia BulletinPublisher: Oxford University Press (OUP)Vol: 38Issue #: 1Start Page: 62End Page: 72Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1093/schbul/sbr168Best OA location URL: https://academic.oup.com/schizophreniabulletin/article-pdf/38/1/62/5351297/sbr168.pdfCitation Count: 27
-
OPENTitle: Quantitative telemedicine ratings in Batten diseaseJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 77Issue #: 20Start Page: 1808End Page: 1811Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0b013e3182377e29Best OA location URL: https://europepmc.org/articles/pmc3233206?pdf=renderCitation Count: 26
-
OPENTitle: Solvent exposures and parkinson disease risk in twinsJournal Name: Annals of NeurologyPublisher: WileyVol: 71Issue #: 6Start Page: 776End Page: 784Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/ana.22629Best OA location URL: http://deepblue.lib.umich.edu/bitstream/2027.42/92108/1/22629_ftp.pdfCitation Count: 154
- CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease2011OPENTitle: CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative diseaseJournal Name: Integrative BiologyPublisher: Oxford University Press (OUP)Vol: 3Issue #: 12Start Page: 1188End Page: 1196Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1039/c1ib00018gBest OA location URL: https://europepmc.org/articles/pmc3334303?pdf=renderCitation Count: 79
- Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats2011RESTRICTEDTitle: Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned ratsJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 62Issue #: 2Start Page: 1052End Page: 1061Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2011.10.016Citation Count: 23
-
RESTRICTEDTitle: Cognitive dysfunction in Tunisian LRRK2 associated Parkinson’s diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 18Issue #: 3Start Page: 243End Page: 246Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2011.10.009Citation Count: 46
-
RESTRICTEDTitle: Evidence-based guideline update: Treatment of essential tremorJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 77Issue #: 19Start Page: 1752End Page: 1755Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1212/wnl.0b013e318236f0fdBest OA location URL: https://n.neurology.org/content/neurology/77/19/1752.full.pdfCitation Count: 268
- Rebound symptoms following battery depletion in the NIH OCD DBS cohort: Clinical and reimbursement issues2011RESTRICTEDTitle: Rebound symptoms following battery depletion in the NIH OCD DBS cohort: Clinical and reimbursement issuesJournal Name: Brain StimulationPublisher: Elsevier BVVol: 5Issue #: 4Start Page: 599End Page: 604Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.brs.2011.10.004Citation Count: 45
-
RESTRICTEDTitle: The role of the basal ganglia in learning and memory: Insight from Parkinson’s diseaseJournal Name: Neurobiology of Learning and MemoryPublisher: Elsevier BVVol: 96Issue #: 4Start Page: 624End Page: 636Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.nlm.2011.08.006Best OA location URL: https://europepmc.org/articles/pmc3772079?pdf=renderCitation Count: 157
-
OPENTitle: Brain biochemistry in autopsied patients with essential tremorJournal Name: Movement DisordersPublisher: WileyVol: 27Issue #: 1Start Page: 113End Page: 117Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1002/mds.24004Best OA location URL: https://europepmc.org/articles/pmc3261329?pdf=renderCitation Count: 52
-
OPENTitle: Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)Journal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 77Issue #: 20Start Page: 1801End Page: 1807Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0b013e318237f649Best OA location URL: https://europepmc.org/articles/pmc3233207?pdf=renderCitation Count: 53
- Striatal Pleiotrophin Overexpression Provides Functional and Morphological Neuroprotection in the 6-Hydroxydopamine Model2011OPENTitle: Striatal Pleiotrophin Overexpression Provides Functional and Morphological Neuroprotection in the 6-Hydroxydopamine ModelJournal Name: Molecular TherapyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 544End Page: 554Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1038/mt.2011.216Best OA location URL: http://www.cell.com/article/S1525001616305111/pdfCitation Count: 29
-
OPENTitle: A soluble α-synuclein construct forms a dynamic tetramerJournal Name: Proceedings of the National Academy of SciencesPublisher: Proceedings of the National Academy of SciencesVol: 108Issue #: 43Start Page: 17797End Page: 17802Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1073/pnas.1113260108Best OA location URL: https://europepmc.org/articles/pmc3203798?pdf=renderCitation Count: 428
-
OPENTitle: Neuroprotective activities of regulatory T cellsJournal Name: Trends in Molecular MedicinePublisher: Elsevier BVVol: 17Issue #: 12Start Page: 687End Page: 688Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.molmed.2011.08.005Best OA location URL: https://europepmc.org/articles/pmc5892451?pdf=renderCitation Count: 48
- Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: Unexpected ‘molecular switch’ from a closely related mGlu4 positive allosteric modulator2011OPENTitle: Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: Unexpected ‘molecular switch’ from a closely related mGlu4 positive allosteric modulatorJournal Name: Bioorganic & Medicinal Chemistry LettersPublisher: Elsevier BVVol: 21Issue #: 23Start Page: 6955End Page: 6959Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.bmcl.2011.09.131Best OA location URL: https://europepmc.org/articles/pmc3319082?pdf=renderCitation Count: 16
- Relationship Between CSF Biomarkers of Alzheimer's Disease and Rates of Regional Cortical Thinning in ADNI Data2011OPENTitle: Relationship Between CSF Biomarkers of Alzheimer's Disease and Rates of Regional Cortical Thinning in ADNI DataJournal Name: Journal of Alzheimer's DiseasePublisher: IOS PressVol: 26Issue #: s3Start Page: 77End Page: 90Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.3233/jad-2011-0006Best OA location URL: https://europepmc.org/articles/pmc4587763?pdf=renderCitation Count: 47
- Discovery, Synthesis, and Structure–Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal Model2011OPENTitle: Discovery, Synthesis, and Structure–Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu4) with Oral Efficacy in an Antiparkinsonian Animal ModelJournal Name: Journal of Medicinal ChemistryPublisher: American Chemical Society (ACS)Vol: 54Issue #: 21Start Page: 7639End Page: 7647Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1021/jm200956qBest OA location URL: https://europepmc.org/articles/pmc3226828?pdf=renderCitation Count: 58
-
RESTRICTEDTitle: α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's DiseaseJournal Name: Pharmacological ReviewsPublisher: American Society for Pharmacology & Experimental Therapeutics (ASPET)Vol: 63Issue #: 4Start Page: 938End Page: 966Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1124/pr.110.003269Best OA location URL: https://europepmc.org/articles/pmc3186078?pdf=renderCitation Count: 171
-
RESTRICTEDTitle: Cell Therapeutics in Parkinson's DiseaseJournal Name: NeurotherapeuticsPublisher: Elsevier BVVol: 8Issue #: 4Start Page: 539End Page: 548Publication Date:Open Access(OA) Status: RESTRICTEDLicense: publisher-specific-oaDOI - Digital Object Identifier: 10.1007/s13311-011-0069-6Best OA location URL: https://link.springer.com/content/pdf/10.1007/s13311-011-0069-6.pdfCitation Count: 78
-
OPENTitle: Plasticity in Early Alzheimer DiseaseJournal Name: Topics in Geriatric RehabilitationPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 27Issue #: 4Start Page: 257End Page: 267Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1097/tgr.0b013e31821e588eBest OA location URL: https://europepmc.org/articles/pmc3419487?pdf=renderCitation Count: 36
-
RESTRICTEDTitle: Regulation of myocyte enhancer factor-2 transcription factors by neurotoxinsJournal Name: NeuroToxicologyPublisher: Elsevier BVVol: 32Issue #: 5Start Page: 563End Page: 566Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuro.2011.05.019Best OA location URL: https://europepmc.org/articles/pmc3200477?pdf=renderCitation Count: 15
- Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders2011RESTRICTEDTitle: Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disordersJournal Name: Biochemical PharmacologyPublisher: Elsevier BVVol: 82Issue #: 8Start Page: 873End Page: 882Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.bcp.2011.06.001Best OA location URL: https://europepmc.org/articles/pmc3264546?pdf=renderCitation Count: 78
-
OPENTitle: β-Hexachlorocyclohexane levels in serum and risk of Parkinson's diseaseJournal Name: NeuroToxicologyPublisher: Elsevier BVVol: 32Issue #: 5Start Page: 640End Page: 645Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.neuro.2011.04.002Best OA location URL: https://doi.org/10.1016/j.neuro.2011.04.002Citation Count: 53
-
OPENTitle: Apathy and Depression: Separate Factors in Parkinson's DiseaseJournal Name: Journal of the International Neuropsychological SocietyPublisher: Cambridge University Press (CUP)Vol: 17Issue #: 6Start Page: 1058End Page: 1066Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1017/s1355617711001068Best OA location URL: https://europepmc.org/articles/pmc3302577?pdf=renderCitation Count: 125
-
OPENTitle: GFAP mutations, age at onset, and clinical subtypes in Alexander diseaseJournal Name: NeurologyPublisher: Ovid Technologies (Wolters Kluwer Health)Vol: 77Issue #: 13Start Page: 1287End Page: 1294Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1212/wnl.0b013e3182309f72Best OA location URL: https://europepmc.org/articles/pmc3179649?pdf=renderCitation Count: 207